Genexine-Kalbe Indonesia JV To Target Biologic Production
This article was originally published in PharmAsia News
South Korean biotech firm Genexine is to set up its fifth joint venture as part of a global push, this time with Kalbe Farma in Indonesia. The venture, KG Bio, will develop and seek regulatory approvals of Genexine's hyFc technology based protein therapies, and Genexine plans to use the new business to strengthen its ASEAN and international business.
You may also be interested in...
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.